Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for FibroGen, Inc. (FGEN) provides regulatory documents that trace the company’s evolution into Kyntra Bio, Inc. A Form 8-K filed in January 2026 reports a Certificate of Amendment to the Amended and Restated Certificate of Incorporation, changing the company’s name from FibroGen, Inc. to Kyntra Bio, Inc. The same filing notes that the company’s common stock, formerly trading under the symbol FGEN, began trading on Nasdaq under the symbol KYNB on January 8, 2026, with the CUSIP number unchanged.
Other Form 8-K filings in this archive document key corporate events and financial updates. These include reports on quarterly financial results, amendments to financing agreements, and the completion of the sale of FibroGen International (Hong Kong) Ltd. (FibroGen China) to AstraZeneca Treasury Limited. The filings describe the total consideration for that transaction, the inclusion of all roxadustat assets in China, and the subsequent repayment of a senior secured term loan.
Investors can use these filings to understand how the company presents its business, capital structure, and strategic transactions to regulators. While detailed annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transaction reports (such as Form 4) are not listed in the provided data, the available 8-Ks illustrate how FibroGen, now Kyntra Bio, communicates material events, including regulatory approvals related to the China divestiture and financial condition updates.
On Stock Titan, these historical FGEN filings are paired with AI-powered tools that help interpret complex disclosures, highlight significant items in event-driven reports, and connect corporate actions—such as the name change, asset sale, and financing amendments—to the broader narrative of the company’s transformation into Kyntra Bio.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company’s ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.
FibroGen, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is included as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The company states the press release is furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. This 8-K does not include numerical financial results within the filing text; investors should review Exhibit 99.1 for the detailed figures and disclosures.